LONDON, UK & NEW YORK, USA – [Date] – In a significant stride towards understanding the complex interplay between ageing and cancer, an international consortium of researchers has uncovered a critical link between age-related mutant blood cells and the progression of aggressive cancers. A collaborative effort spanning the Francis Crick Institute, University College London (UCL), Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK), this pioneering study reveals that the expansion of these mutant blood cells, a phenomenon inherently tied to the ageing process, can infiltrate cancerous tumours and is directly associated with markedly worse prognoses for patients.
Published today in the prestigious New England Journal of Medicine, the findings introduce a new dimension to cancer biology, identifying a novel mechanism by which the body’s own age-acquired genetic changes contribute to tumour evolution and resistance. This discovery not only offers fresh insights into why certain cancers become more aggressive but also paves the way for innovative diagnostic tools and targeted therapies, particularly relevant for an increasingly ageing global population.
The Silent Threat: Unravelling Clonal Haematopoiesis and its Cancerous Connection
Understanding the intricate biological interface between age-related genetic changes and diseases that commonly afflict older individuals, such as cancer and cardiovascular disease, is paramount for developing effective preventative and therapeutic strategies. As global demographics shift towards an older population, the prevalence of these age-associated conditions is set to rise, making such research ever more critical.
Central to this groundbreaking study is a condition known as Clonal Haematopoiesis of Indeterminate Potential (CHIP). CHIP is characterised by the accumulation of specific mutations within blood stem cells over time. This process is influenced by a combination of natural ageing and various external environmental factors, leading to the clonal expansion of these mutant cells within the bloodstream. While CHIP has previously been identified as a risk factor for a range of age-related disorders, including cardiovascular disease, its direct impact on the evolution and aggression of solid cancers had, until now, remained largely unexplored. The research team embarked on an ambitious journey to bridge this critical knowledge gap, aiming to delineate how these widespread age-related genetic changes in the blood might influence the trajectory of solid tumour development.
A Meticulous Investigation: Tracing CHIP’s Role in Cancer Progression
The journey of discovery began with a meticulous, multi-phase investigation, drawing upon extensive patient cohorts and advanced analytical techniques. The initial phase focused on a detailed examination of blood samples from over 400 patients diagnosed with lung cancer, as part of the Cancer Research UK (CRUK) funded TRACERx (Tracking Cancer Evolution through therapy) and PEACE (Postmortem Examination of Advanced Cancer Environments) studies. This was then complemented by an even larger validation cohort of 49,000 patients with diverse cancer types from MSK, providing an unparalleled scale to the research.
Initial Observations: CHIP as a Prognostic Indicator
The research team’s first significant step involved screening the blood samples of the lung cancer patients for the presence of CHIP mutations. By carefully matching these genetic findings with comprehensive clinical data, including patient demographics, cancer stage at diagnosis, and treatment outcomes, a striking correlation emerged. Scientists observed that patients harbouring CHIP mutations in their blood exhibited a statistically significant shorter overall survival period. Crucially, this association remained robust and independent of other well-known prognostic factors, such such as the patient’s age at diagnosis or the initial stage of their cancer. This initial finding was a powerful indicator, suggesting that CHIP, a condition often asymptomatic and previously linked primarily to blood disorders and cardiovascular risks, held a systemic influence on cancer prognosis, even when the mutations were confined to circulating blood cells. It underscored the potential for CHIP to serve as an early, systemic biomarker for identifying patients at higher risk of adverse cancer outcomes.
Unmasking Tumour-Infiltrating Clonal Haematopoiesis (TI-CH)
The compelling initial observations spurred the researchers to delve deeper. If CHIP in the blood was associated with worse outcomes, could these mutant blood cells be directly influencing the tumours themselves? The team hypothesised that these age-acquired mutant cells might not merely circulate systemically but could actively infiltrate the cancerous lesions. To test this, they meticulously analysed tumour biopsies from patients with CHIP, searching for the very same mutations previously identified in their blood.
Their hypothesis proved correct. In a significant 42% of patients with CHIP, the identical mutations were found within their lung tumours, a phenomenon the researchers termed Tumour-Infiltrating Clonal Haematopoiesis, or TI-CH. This discovery was a pivotal moment, shifting the focus from a purely systemic blood disorder to a direct interaction within the tumour microenvironment. Further analysis revealed an even more critical distinction: it was the presence of TI-CH—the infiltration of these mutant blood cells into the tumour—and not simply CHIP in the blood, that was profoundly associated with a greater risk of cancer relapse and, tragically, increased cancer-related mortality. This finding suggested that the physical presence and interaction of these mutant cells within the tumour were key drivers of its aggressive behaviour.
Post-Mortem Validation: TI-CH in Metastatic Disease
To further solidify the link between TI-CH and aggressive cancer, the team leveraged samples from the PEACE study. This unique post-mortem investigation allows researchers to examine cancer at its most advanced stages, particularly in areas where the disease has spread (metastasis), which is the primary cause of cancer death. The findings from the PEACE study provided compelling corroboration: metastatic tumours, often representing the most lethal aspect of cancer progression, frequently harboured TI-CH mutations. This direct evidence reinforced the critical role of TI-CH in facilitating not just local tumour progression but also distant dissemination and treatment resistance, painting a clearer picture of how these age-related blood cell changes contribute to the deadliest forms of the disease.
Deconstructing the Mechanism: The Role of Myeloid Cells and TET2 Mutations
Having established a robust correlation between TI-CH and adverse patient outcomes, the next crucial step was to unravel the underlying biological mechanisms. How exactly do these age-related mutant blood cells within the tumour microenvironment contribute to its aggression?
Cellular Composition and Immune Subversion
The scientists meticulously investigated the cellular composition of the lung tumours in patients with TI-CH. Their analysis revealed a distinct and significant expansion of myeloid cells, a specific type of immune cell, within these tumours. Myeloid cells are a crucial component of the tumour microenvironment, representing a double-edged sword in the immune response against cancer. While some immune cells are primed to recognise and actively fight cancer cells, myeloid cells have a more complex role. They are known regulators of inflammation, and in certain contexts, they can inadvertently support tumour progression, growth, and spread by creating an immunosuppressive or pro-tumourigenic environment. The observed expansion of these cells, particularly in the presence of TI-CH, pointed towards a potential subversion of the immune response, shifting the balance in favour of the tumour.
Identifying Key Genetic Drivers: The Role of TET2
The investigation then narrowed down to identifying which specific mutations within CHIP were most influential. Researchers discovered that when mutations affected a particular gene called TET2, these mutant blood cells were significantly more likely to infiltrate the tumour. The TET2 gene plays a vital role as an important regulator of blood cell production, and mutations in it are well-known drivers of certain blood cancers and are frequently observed in CHIP. To confirm the specific cellular location of these TET2 mutations within the tumour, the team employed single-cell analysis on hundreds of individual cells from the tumours of two patients with TI-CH. This high-resolution analysis unequivocally confirmed that the TET2 mutations were predominantly present within myeloid cells, but not in other immune cell types, solidifying the link between this specific genetic alteration, myeloid cell expansion, and tumour infiltration.
Experimental Confirmation: Organoid Models Provide Causal Evidence
To move beyond correlation and establish a direct causal link, the research team engaged in a crucial collaboration with blood cancer and CHIP experts in a Crick laboratory led by Dominique Bonnet. Together, they designed and conducted experimental studies using organoids – miniature, lab-grown lung tumours that mimic the complex structure and behaviour of real tumours. By introducing TET2 mutant myeloid cells into these organoid cultures, they were able to observe their direct impact. The results were compelling: the TET2 mutant myeloid cells actively remodelled the tumour microenvironment, creating conditions conducive to accelerated tumour organoid growth. This experimental validation provided powerful, direct evidence that TET2-mutated myeloid cells are not just bystanders but active participants in driving tumour progression, offering a tangible mechanism for the observed clinical outcomes.
Broadening the Horizon: Validation Across Diverse Cancer Types
The robust findings from the lung cancer and experimental models necessitated validation across a broader spectrum of human cancers to assess the generalizability and clinical significance of TI-CH. In a pivotal collaboration with researchers at Memorial Sloan Kettering Cancer Center in the US, the team accessed and analysed an expansive dataset comprising over 49,000 patients diagnosed with various types of cancer.
The results from this large-scale validation were striking and consistent. Across this vast and diverse patient cohort, the presence of TI-CH emerged as an independent predictor of shorter overall survival. This robust finding underscored the widespread clinical relevance of TI-CH, transcending specific cancer types and reaffirming its potential as a universal prognostic marker.
Interestingly, the prevalence of both CHIP and TI-CH varied considerably between different cancer types. Researchers observed that these mutations were more common in cancers notoriously difficult to treat and associated with poorer prognoses, such as lung cancer (the initial focus of the study), head and neck cancer, and pancreatic cancer. This observation further strengthens the hypothesis that TI-CH plays a particularly detrimental role in the most aggressive and challenging forms of the disease, highlighting areas where therapeutic interventions targeting this pathway could yield the greatest clinical benefit.
Expert Perspectives and Future Directions
The implications of this research are profound, offering a fresh lens through which to view cancer evolution and providing a robust foundation for future therapeutic and diagnostic developments.
Oriol Pich, a Postdoctoral Project Research Scientist in the Crick’s Cancer Evolution and Genome Instability Laboratory and one of the lead authors, articulated the immediate significance of the findings: "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients. This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer." Pich’s statement underscores the ubiquity of CHIP in the ageing population, particularly among cancer patients, making the discovery highly relevant to a substantial patient demographic.
Charlie Swanton, Deputy Clinical Director at the Crick, Chief Clinician at Cancer Research UK, and Chief Investigator for TRACERx, emphasised the novelty and potential of this work: "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations’, age-related CHIP and cancer, providing insight into how ageing might impact cancer risk. As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers." Swanton’s comments highlight the paradigm shift in understanding the interplay between distinct clonal expansions and offer a hopeful outlook for future preventative and interventional strategies against age-related cancers.
Implications for Research and Clinical Practice
The next steps for this transformative research are clearly defined and hold immense promise for clinical translation:
- Confirming Causality and Detailing Mechanisms: While the current study provides strong correlational and experimental evidence, future work will focus on definitively confirming that CHIP directly contributes to adverse cancer outcomes. Researchers will also aim to meticulously detail the exact molecular and cellular mechanisms by which CHIP, particularly through TI-CH and TET2 mutant myeloid cells, functionally implicates itself in the development and aggression of various cancers.
- Developing Novel Therapeutic Avenues: The identification of TI-CH and the specific role of TET2 mutant myeloid cells opens exciting new therapeutic avenues. Strategies could include targeting these specific mutant cells within the tumour microenvironment, modulating their pro-tumourigenic functions, or developing drugs that interfere with the pathways they activate to promote tumour growth and spread. This could lead to personalised therapies tailored to patients based on their CHIP/TI-CH status.
- Enhancing Diagnostic and Prognostic Tools: The presence of CHIP, and more specifically TI-CH, could serve as a powerful new prognostic biomarker. Screening for these mutations in cancer patients could help identify those at higher risk of relapse or poorer survival, allowing clinicians to implement more intensive monitoring, consider more aggressive treatment regimens, or explore novel targeted therapies earlier in the disease course.
- Exploring Preventative Strategies: In the longer term, understanding the origins and progression of CHIP and its infiltration into tumours could inform preventative strategies. If specific environmental or lifestyle factors exacerbate CHIP progression or TI-CH development, interventions could be designed to mitigate these risks, potentially preventing the development of aggressive cancers in susceptible individuals.
- Reshaping Cancer as a Disease of Ageing: This research fundamentally reshapes our understanding of cancer, integrating it more deeply into the broader context of age-related diseases. It underscores the critical need for an integrative approach to studying and treating cancer, considering systemic age-related changes alongside tumour-specific mutations.
This pioneering work, supported by generous funding from Cancer Research UK and the National Institute of Health and Care Research UCLH Biomedical Research Centre, alongside additional funders, represents a significant leap forward in oncology. By illuminating the intricate connections between ageing blood cells and tumour aggression, it not only expands our scientific understanding but also ignites hope for new strategies to improve the lives of countless patients grappling with cancer in an ageing world.
The study was led by the dedicated research team of Oriol Pich, Elsa Bernard, and Maria Zagorulya, whose collaborative spirit and scientific rigour have laid the groundwork for a new era in cancer research.
About the Author
